Impaired antibody response in an AIDS patient compromised the accuracy of the test. The OraQuick Advance Rapid HIV-1 Antibody Test has transformed HIV testing from a cumbersome process to a rapid ...
The WHO approves lenacapavir every six months as a new step in HIV prevention, simplifying diagnoses and expanding ...
Gilead's experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday. None of the roughly 2,000 women in the trial who received the ...
On Sept. 18, we observe National HIV/AIDS and Aging Awareness Day (NHAAD), a day to highlight the unique challenges and ...
Gilead Sciences Inc.’s stock GILD jumped 4.5% early Thursday after the company said its experimental twice-yearly injection for HIV prevention was found 100% effective in a late-stage trial. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback